National Institutes of Health

NIH: Autoimmunity Centers of Excellence, Clinical Research Program (UM1)

Program Summary

This FOA solicits applications to participate in the Autoimmunity Centers of Excellence (ACE) program, a cooperative network intended to improve the understanding and treatment of autoimmune diseases (  The ACE program was founded on the premise that collaboration among basic and clinical scientists can accelerate both fundamental and applied research.  For this reissuanc, the formerly integrated Centers are divided into Basic and Clinical research programs.  This FOA solicits applications for the Clinical research program; a companion FOA solicits applications for the Basic research program.  The members of the Basic and Clinical ACE will work together to design and conduct studies of mechanisms of action of immune-modulating agents tested in clinical trials.

A program director/principal investigator (PD/PI) may NOT apply to both this ACE Clinical program FOA and the companion Basic program FOA. 


Only one application per institution (normally identified by having a unique DUNS number or NIH IPF number) is allowed.  The same institution may also apply to the companion FOA. A single PD/PI, and PDs/PIs on a multiple-PD/PI application, may NOT also serve as PDs/PIs on an application to the companion FOA.

An individual may serve as PD/PI on an application to either this ACE Clinical program FOA or the companion Basic program FOA but not both.  PD(s)/PI(s) should commit at least 2.4 person months effort (total for multiple PDs/PIs).  A PD/PI may lead no more than one of the proposed Projects.  The PD/PI (or one of the PDs/PIs if multiple PDs/PIs) should also lead the Administrative Core.   

Award Information

Cooperative agreement.  NIAID anticipates awarding up to $1.2 million in direct costs in FY 2014 to fund up to 4 new or renewal grants within the ACE Clinical program. Additional funds will be awarded to support the Clinical Project Fund and an Opportunity Fund.

Applicants to the ACE Clinical program can request up to $700,000 (direct costs) each per year for the Primary and Alternate Clinical Projects. It is anticipated that this FOA will fund successful applicants up to $50,000 per year direct costs for planning further development of successful Clinical Trial Projects. It is anticipated that Funds for implementing the full Clinical Trial Projects will be provided by the ACE Funds Management Core. 

In addition, applicants can request up to $50,000 per year in direct costs for the Administrative Core. Applications containing an optional Collaborative Project may request up to $250,000 per year in additional direct costs.  Support for the optional ACE Funds Management Core is limited to $250,000 per year in direct costs.

The maximum project period is five years.

Internal Selection Procedure

The Office of the Vice President for Research and the Carver College of Medicine have established an internal review procedure to select the UI nominee. Applications will be reviewed according to the sponsor’s selection criteria. Consideration will also be given to UI institutional strengths and strategic directions. Potential applicants must submit, using the preselection link below, the following information:
1. A two page CV; and
2. A description of the proposed project. It should have the following elements:
The above materials must be submitted no later than 5:00 p.m. on Thursday, April 18, 2013. The selected nominee will be asked to complete the full application package in accordance with the sponsor's deadline of Thursday, June 13, 2013.

Proposal Due to OVPRED04/18/2013 Not open for submission deadline passed
Date Due to DSP or UIF06/06/2013
Date Due to Sponsor06/13/2013
Required LOI Due DateN/A
Non-Required LOI Due Date05/13/2013
Sponsor URL:

Admin/Reviewer Login here first

Back to the WINS main page